Bureaucrats as Venture Capitalists?

Corporate welfare is something we love to hate. On the political left, economist and former Secretary of Labor Robert Reich derides it as "business subsidies that don't make sense." The consumer watchdog group Common Cause estimates that federal subsidies to U. S. businesses amount to more than $150 billion annually in various manifestations, including "direct payments to companies, provision of public goods or services at below-market value, federal purchases of goods or services at above-mark

Written byHenry Miller
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Aggressive, highly competitive entrepreneurs and business executives also oppose corporate welfare, which, they say, distorts the marketplace by substituting bureaucrats' amateur judgments for market forces. Worse still, American industry falls victim to the vicious circle created by government taxing and spending to "support" commercial growth. With corporate taxes high, companies lobby for give-backs to remain competitive--leading to higher taxes and a new tax-and-spend cycle.

The form of the give-backs also warrants concern. Many just don't make sense. A case in point is the Commerce Department's Advanced Technology Program (ATP), a perennial favorite of the Clinton administration. The administration has just proposed a 34.7 percent budget boost next year, to $260 million, with a target of $500 million by 2002.

Among the general competition awards announced last year, project after project focused on relatively late-stage applied research that, while unlikely to contribute substantial new knowledge, may advance product development for an ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies